Form 1449 (modified)	Docket: 084/002	U.S.S.N. 10/023,969
Information Disclosure Statement By Applicant	Title: CHIMERIC CYTOLYTIC VIRUSES FOR CANCER TREATMENT Inventors: Irving, et al.	RECEIVED TECH CENTER 1600/2900
(Use Several Sheets if Necessary)	Filing Date: 17 December 2001 Group: 1648	02 AUG -2 PM 3:23

U.S. Patent Documents

Examiner Initial	Ref.	Patent No.	Filing Date	Issue Date	Class/ Subclass	Inventors:	Title:
W	A	4,963,481	Nov 12/86	Oct 16/90	435/69.1	de Villeirs	Promoter System
	B	5,631,236	Aug 26/93	May 20/97	514/44	Woo, et al.	Gene Therapy for Solid Tumors, Using a DNA Sequence Encoding HSV-TK or VZV-TK
	C	5,670,488	Oct 13/93	Sep 23/97	514/44	Gregory, et al.	Adenovirus Vector for Gene Therapy
	D	5,698,443	Jun 27/95	Dec 16/97	435/320.1	Henderson, et al.	Tissue Specific Viral Vectors
	E	5,712,136	Apr 17/96	Jan 27/98	435/172.3	Wickham, et al.	Adenoviral-Mediated Cell Targeting Commanded by the Adenovirus Penton Base Protein
	F	5,728,379	Jun 7/95	Mar 17/98	424/93.2	Martuza, et al.	Tumor- or Cell-Specific Herpes Simplex Virus Replication
	G	5,759,776	Jun 5/95	Jun 2/98	435/6	Smith, et al.	Targets for Breast Cancer Diagnosis and Treatment
	H	5,776,683	Jul 11/96	Jul 7/98	435/6	Smith, et al.	Methods for Identifying Genes Amplified in Cancer Cells
	I	5,801,029	Jun 7/95	Sep 1/98	435/172.3	McCormick	Cytopathic Viruses for Therapy and Prophylaxis of Neoplasia
	J	5,846,945	Jun 7/95	Dec 8/98	514/44	McCormick	Cytopathic Viruses for Therapy and Prophylaxis of Neoplasia
	K	5,849,522	Jun 6/95	Dec 15/98	435/69.1	Fleckenstein, et al.	Enhancer for Eukaryotic Expression Systems
	L	5,871,726	Jun 26/96	Feb 16/99	424/93.2	Henderson, et al.	Tissue Specific and Tumor Growth Supperssion by Adenovirus Comprising Prostate Specific Antigen
	M	5,880,102	Jan 17/95	Mar 9/99	514/44	George, et al.	Adenoviral Vector System
	N	5,994,128	Jun 14/96	Nov 30/99	435/325	Fallaux, et al.	Packaging Systems for Human Recombinant Adenovirus to be Used in Gene Therapy
	O	5,997,859	Jun 6/95	Dec 7/99	424/93.2	Barber, et al.	Method for Treating a Metastic Carcinoma Using a Conditionally Lethal Gene
	P	5,998,205	Nov 28/95	Dec 7/99	435/325	Hallenbeck, et al.	Vectors for Tissue-Specific Replication
	Q	6,040,174	May 27/94	Mar 21/00	435/325	Imler, et al.	Defective Adenoviruses and Corresponding Complementation Lines
	R	6,096,718	Jun 5/97	Aug 1/00	514/44	Weitzman, et al.	Tissue Specific Adenovirus Vectors for Breast Cancer Treatment
	S	6,140,126	Oct 26/99	Oct 31/00	435/375	Bennett, et al.	Antisense Modulation of Y-Box Binding Protein 1 Expression

Examiner	Date Considered
	9/1/03

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)	Docket: 084/002	U.S.S.N. 10/023,969
Information Disclosure Statement By Applicant	Title: CHIMERIC CYTOLYTIC VIRUSES FOR CANCER TREATMENT Inventors: Irving, et al.	
(Use Several Sheets if Necessary)	Filing Date: 17 December 2001	Group: 1648

Foreign Patent or Published Foreign Patent Application

Examiner Initial	Ref.	Document No.	Publ. Date	Jurisdiction	Title:	Translation
LW	T	WO 98/14593	Apr 9/98	PCT	Human Telomerase Catalytic Subunit	
	U	WO 98/39466	Sep 11/98	PCT	Adenovirus Vectors Specific for Cells Expressing Androgen Receptor and Methods of Use Thereof	
	V	WO 99/08692	Feb 25/99	PCT	Reovirus for the Treatment of Neoplasia	
	W	WO 99/25860	May 27/99	PCT	Vector for Tissue-Specific Replication and Gene Expression	
	X	WO 99/27113	Jun 3/99	PCT	Mouse Telomerase Reverse Transcriptase	
	Y	WO 99/33998	Jul 8/99	PCT	Regulatory DNA Sequences of the Human Catalytic Telomerase Sub-Unit Gene, Diagnostic and Therapeutic Use Therof	
	Z	WO 00/46355	Aug 10/00	PCT	Telomerase Reverse Transcriptase Regulatory Sequences	
	AA	EP 657541 A1	Jun 14/95	EP	Novel Entities for Cancer Therapy	
	AB	EP 702084 B1	Mar 20/96	EP	Reconbinant Retroviruses	
	AC	GB 2321642 B	Aug 5/98	GB	Human Telomerase Reverse Transcriptase Promoter	

Other Documents

Examiner Initial	Ref.	Author, Title, Date, Source
LW	AD	Akrigg, et al., The structure of the major immediate early gene of human cytomegalovirus strain AD169, Virus Research 2:107 (1985)
	AE	Alemany, et al., Complementary adenoviral vectors for oncolysis, Cancer Gene Ther. 6:21 (1999)
	AF	Balter, Gene therapy on trial, Science 288:951 (2000)
	AG	Bilbao, et al., Targeted adenoviral vectors for cancer gene therapy, Adv. Exp. Med. Biol. 451:365 (1998)
	AH	Danthinne, et al., Production of first generation adenovirus vectors: a review, Gene Ther. 7:1707 (2000)
	AI	Didier, et al., Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box, Proc. Natl. Acad. Sci. USA 85:7322 (1988)
	AJ	Emery, et al., Current status review molecular biology of cytomegalovirus, Int. J. Exp. Pathol. 71:905 (1990)
	AK	Farthing, et al., Functions of human papillomavirus E6 and E7 oncoproteins, Trends Microbiol. 2:170 (1994)
	AL	Gu, et al., Tumor-specific Transgene Expression from the Human Telomerase Reverse Transcriptase Promoter Enables Targeting of the Therapeutic Effects of the Bax Gene to Cancers, Cancer Res. 60:5359 (2000)
	AM	Hallenbeck, et al., Oncolytic Adenoviruses Dependent upon Two Prevalent Alterations in Human Cancer; Disregulation of the Rb-Pathway and Telomerase, Amer. Soc. Gene Ther. 5: Abstract 165 (2002)
	AN	Holm, et al., Involvement of the Human Transcription Factor YB-1 in Adenovirus DNA Replication: New Strategies in Adenoviral-Oncolytic Based Therapy, Amer. Soc. Gene Ther. 5: Abstract 1325 (2002)

Examiner	Date Considered 4/11/03

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)	Docket: 084/002	U.S.S.N. 10/023,969
Information Disclosure Statement By Applicant	Title: CHIMERIC CYTOLYTIC VIRUSES FOR CANCER TREATMENT Inventors: Irving, et al.	
(Use Several Sheets if Necessary)	Filing Date: 17 December 2001	Group: 1648

Examiner Initial	Ref.	Author, Title, Date, Source
HW	AO	Holm, et al., E1-indepentant adenoviral replication in multidrug resistant cells: Involvment of the human transcription factor YB-1, European Society of Gene Therapy Meeting, Abstract P 90 (2000)
	AP	Holm, et al., YB-1 Relocates to the Nucleus in Adenovirus-infected Cells and Facilitates Viral Replication by Inducing E2 Gene Expression through the E2 Late Promoter, J. Biol. Chem. 277:10427 (2002)
	AQ	Horikawa, et al., Cloning and Characterization of the Promoter Region of Human Telomerase Reverse Transcriptase Gene, Cancer Res., 59:826 (1999)
	AR	Ise, et al., Transcription factor y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen, Cancer Res. 59:342 (1999)
	AS	Izumi, et al., Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3'→5' exonuclease activity, Nucleic Acids Res. 29:1200 (2001)
	AT	Jing, et al., Transcriptional and Post-Transcriptional Control Executed by a Human Immunodeficiency Virus Type 1 Based Recombinant Retrovirus Leads to the Suppression of Human Cancer Cells, Amer. Soc. Gene Ther. 5: Abstract 828 (2002)
	AU	Jones, et al., Interactions of the human papillomavirus E7 protein with cell cycle regulators, Semin. Cancer Biol. 7:327 (1996)
	AV	Kim, et al., Development of Conditional Replication Competant Adenovirus Controlled by Human Telomerase Promoter (hTERT), Amer. Soc. Gene Ther. 5: Abstract 194 (2002)
	AW	Kirch, et al., Short Human TERT-Promoter Fragments as Efficient Tumor-Specific Transcriptional E1A-Targets for Anti-Cancer Gene Therapy with (VP22)-Ad5/12E1A-Derivatives, Amer. Soc. Gene Ther. 5: Abstract 619 (2002)
	AX	Koike, et al., Nuclear translocation of the Y-box binding protein by ultraviolet irradiation, FEBS Lett. 417: 390 (1997)
	AY	Koga, et al., A novel telomerase specific gene therapy: gene transfer of caspase 8 utilizing the human telomerase catalytic subunit gene promoter, Hu. Gene Ther. 11:1397 (2000)
	AZ	Kwon, et al., Ribozyme-Triggered Selective Induction of Cytotoxin in Cancer Cells by Targeting Trans-Splicing, Amer. Soc. Gene Ther. 5: Abstract 417 (2002)
	BA	Leroy, et al., Cancer Gene Therapy: From Selectivity to Specificity of Gene Expression Control, Amer. Soc. Gene Ther. 5: Abstract 382 (2002)
	BB	Liu, et al., Cancer-Specific Killing by the Suicide Gene (CD) Using the Human Telomerase Reverse Transcriptase Promoter, Amer. Soc. Gene Ther. 5: Abstract 1179 (2002)
	BC	Mantovani, A survey of 178 NF-Y binding CCAAT boxes, Nucl. Acids Res. 26:1135 (1998)
	BD	Meier, et al., Regulation of human cytomegalovirus immediate-early gene expression, Intervirology 39:331 (1996)
	BE	Novick, et al., Membrane penetration of Sendai virus glycoproteins during the early stages of fusion with liposomes as determined by hydrophobic photoaffinity labeling, Proc. Natl. Acad. Sci. USA 85:7433 (1988)
	BF	Powell, et al., A Conditionally Replicative Adenovirus Driven by the Human Telomerase Promoter Provides Broad-Spectrum Anti-Tumor Activity, Amer. Soc. Gene Ther. 5: Abstract 51 (2002)
	BG	Rots, et al., Optimization of Adenoviral Agents for Virotherapy, Amer. Soc. Gene Ther. 5: Abstract 177 (2002)
	BH	Singal, et al., Human Y-box transcription factors: sequences of two new YB-1 alleles, Gene 154:299 (1995)
	BI	Spector, et al., Identification of a human cytomegalovirus Virus DNA segment that complements an adenovirus 5 immediate early mutant, Virology 151:329 (1986)
	BJ	Spector, Activation and regulation of human cytomegalovirus early genes, Intervirology 39:361 (1996)
	BK	Stenberg, The human cytomegalovirus major immediate-early gene, Intervirology 39:343 (1996)

Examiner	Date Considered
	4/11/05

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)	Docket: 084/002 U.S.S.N. 10/023,969
Information Disclosure Statement By Applicant	Title: CHIMERIC CYTOLYTIC VIRUSES FOR CANCER TREATMENT Inventors: Irving, et al.
(Use Several Sheets if Necessary)	Filing Date: 17 December 2001 Group: 1648

Examiner Initial	Ref.	Author, Title, Date, Source
	BL	Stenberg, et al., Multiple spliced and unspliced transcripts from human cytomegalovirus immediate-early region 2 and evidence for a common initiation site within immediate-early region 1, J. Virol. 56:665 (1985)
	BM	Swamynathan, et al., Role of single-stranded DNA regions and Y-box proteins in transcriptional regulation of viral and cellular genes, FASEB J. 12:515 (1998)
	BN	Tevethia, et al., Participation of two human cytomegalovirus immediate early gene regions in transcriptional activationof adenovirus promoters, Virology 161:276 (1987)
	BO	Walther, et al., Therapeutic genes for cancer gene therapy, Mol. Biotechnol. 13:21 (1999)
	BP	Zhang, et al., Bicistronic Conditionally Replication Competent Adenoviral Vectors Which Are Selectively Lytic for Breast and Ovarian Cancer Cells but Which Are Non-Toxic for Normal Breast and Ovarian Epithelial Cells, Amer. Soc. Gene Ther. 5: Abstract 176 (2002)

Examiner	Date Considered 9/1/03

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)	Docket: 084/002 Suppl 1 U.S.S.N. 10/023,969
Information Disclosure Statem nt By Applicant	Title: CHIMERIC CYTOLYTIC VIRUSES FOR CANCER TREATMENT Inventors: Irving, et al.
(Use Several Sheets if Necessary)	Filing Date: 17 December 2001 Group: 1648

U.S. Patent Documents

Examiner Initial	Ref.	Patent No.	Filing Date	Issue Date	Class/ Subclass	Inventors:	Title:
None							

Foreign Patent or Published Foreign Patent Application

Examiner Initial	Ref.	Document No.	Publ. Date	Juris-diction	Title:	Translation
W	CA	WO 00/78327	Dec 28/00	PCT	Agents for treating malignant diseases using protein YB-1	abstract
W	CB	WO 00/78327	Dec 28/00	PCT	Agents for treating malignant diseases using protein YB-1	Derwent abstract

Other Documents

Examiner Initial	Ref.	Author, Title, Date, Source
W	CC	Alemany, et al., Replicative adenoviruses for cancer therapy, Nature Biotechn 18:723 (2000)
	CD	Balague, et al., Human papallomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes, J Virology 75:7602 (2001)
	CE	Pham, et al., C-494. Complementation of adenovirus E1A binding to HCMV EI1 & HCMV IE2, Abstracts of the General Meeting of the Amer Soc for Microbiology; Chicago, Illinois, USA; May 30-June 3, 1999, right-hand column, line 5 – line 15 (1999)
	CF	Steinwaerder, et al., Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes, Mol Therapy 4:211 (2001)
	CG	Wong, et al., The human papillomavirus type 16 E7 protein complements adenovirus type 5 E1A amino-terminus-dependent transactivation of adenovirus type 5 early genes and increases ATF and Oct-1 DNA binding activity, J Virology 70:332 (1996)

RECEIVED
DEC 1 0 2002
TECH CENTER 1600/2900

Examiner	Date Considered 4/1/03

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**